TRAF6 Promotes PRMT5 Activity in a Ubiquitination-Dependent Manner

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Protein arginine methyltransferase 5 (PRMT5) regulates critical cellular functions like transcription and DNA repair.
• Dysregulated PRMT5 is linked to poor prognosis in various human cancers.
• Mechanisms controlling PRMT5 activity remain largely unknown.

Purpose of the Study:

• To elucidate the upstream regulatory mechanisms of PRMT5.
• To investigate the role of E3 ubiquitin ligases in PRMT5 activation.
• To explore potential therapeutic strategies targeting the PRMT5 regulatory pathway.

Main Methods:

• Ubiquitination assays to identify PRMT5 ubiquitination sites and linkage types.
• Co-immunoprecipitation to study protein-protein interactions.
• Site-directed mutagenesis to disrupt PRMT5 ubiquitination.
• Cell proliferation and tumor growth assays.
• Inhibition studies using TRAF6 and PRMT5 inhibitors.

Main Results:

• TRAF6 functions as an E3 ubiquitin ligase that promotes PRMT5 ubiquitination and activation.
• TRAF6 catalyzes K63-linked ubiquitination of PRMT5 at six N-terminal lysine residues.
• TRAF6-mediated ubiquitination is crucial for PRMT5 methyltransferase activity and interaction with MEP50.
• Disruption of PRMT5 ubiquitination suppresses cancer cell proliferation and tumor growth.
• TRAF6 inhibition sensitizes cancer cells to PRMT5 inhibitors.

Conclusions:

• TRAF6-mediated ubiquitination is a critical regulatory mechanism for PRMT5 activation in cancer.
• Targeting the TRAF6-PRMT5 interaction offers a potential therapeutic strategy for cancer treatment.
• Combined inhibition of TRAF6 and PRMT5 may enhance anti-cancer efficacy.